Trinity Biotech plc (TRIB)
NASDAQ: TRIB · Real-Time Price · USD
7.23
-0.04 (-0.55%)
Sep 18, 2026, 4:00 PM EDT - Market closed
Trinity Biotech Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 43.79 | 61.56 | 56.83 | 62.52 | 81.15 | |
Revenue Growth | -28.87% | 8.31% | -9.10% | -22.96% | -20.43% |
Cost of Revenue | 26.9 | 40.11 | 37.38 | 45.25 | 47.7 |
Gross Profit | 16.89 | 21.44 | 19.45 | 17.27 | 33.45 |
Selling, General & Admin | 24.67 | 28.82 | 31.15 | 26.98 | 22.5 |
Research & Development | 3.63 | 4.54 | 4.38 | 4.14 | 4.5 |
Other Operating Expenses | -1.87 | 1.79 | -0.14 | -0.34 | -0 |
Operating Expenses | 26.43 | 35.15 | 35.39 | 30.78 | 27 |
Operating Income | -9.55 | -13.7 | -15.94 | -13.51 | 6.46 |
Interest Expense | -12.81 | -11.91 | -10.15 | -11.53 | -7.09 |
Interest & Investment Income | - | - | 1.17 | - | 0 |
Other Non Operating Income (Expenses) | -0.2 | -1.17 | - | 0.23 | 1.22 |
EBT Excluding Unusual Items | -22.55 | -26.78 | -24.92 | -24.81 | 0.6 |
Merger & Restructuring Charges | -4.25 | -4.18 | - | - | - |
Impairment of Goodwill | -2.14 | -1.6 | -5.83 | - | -3.85 |
Gain (Loss) on Sale of Investments | - | 0.8 | -1.5 | - | - |
Asset Writedown | -0.03 | -0.61 | -3.77 | -5.36 | -2.51 |
Other Unusual Items | -8.19 | 1.64 | -0.91 | -13.61 | 3.84 |
Pretax Income | -37.18 | -30.73 | -36.93 | -43.78 | -1.92 |
Income Tax Expense | 0.2 | 0.49 | -0.06 | -0.19 | -0.07 |
Earnings From Continuing Operations | -37.38 | -31.22 | -36.87 | -43.59 | -1.85 |
Earnings From Discontinued Operations | - | -0.57 | 12.85 | 2.58 | 2.73 |
Net Income | -37.38 | -31.79 | -24.02 | -41.01 | 0.88 |
Net Income to Common | -37.38 | -31.79 | -24.02 | -41.01 | 0.88 |
Net Income Growth | - | - | - | - | - |
Shares Outstanding (Basic) | 1 | 1 | 0 | 0 | 0 |
Shares Outstanding (Diluted) | 1 | 1 | 0 | 0 | 0 |
Shares Change | 3.43% | 134.61% | 13.46% | 61.40% | - |
EPS (Basic) | -60.36 | -53.10 | -94.13 | -182.34 | 6.28 |
EPS (Diluted) | -60.36 | -60.96 | -94.13 | -182.34 | 6.28 |
EPS Growth | - | - | - | - | - |
Additional Metrics
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -6.02 | -4.6 | -12.36 | -2.02 | 11.43 |
Free Cash Flow Per Share | -9.72 | -7.68 | -48.44 | -8.99 | 82.00 |
Gross Margin | 38.57% | 34.83% | 34.22% | 27.62% | 41.23% |
Operating Margin | -21.80% | -22.26% | -28.05% | -21.61% | 7.96% |
Profit Margin | -85.36% | -51.64% | -42.26% | -65.59% | 1.08% |
Free Cash Flow Margin | -13.74% | -7.47% | -21.75% | -3.23% | 14.08% |
EBITDA | -8.24 | -13.03 | -14.17 | -11.22 | 9.18 |
EBITDA Margin | -18.83% | -21.17% | -24.92% | -17.94% | 11.31% |
D&A For EBITDA | 1.3 | 0.68 | 1.78 | 2.29 | 2.72 |
EBIT | -9.55 | -13.7 | -15.94 | -13.51 | 6.46 |
EBIT Margin | -21.80% | -22.26% | -28.05% | -21.61% | 7.96% |